Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity
Together, these results support <sup>Allo15</sup>MCAR-NKT cells as a next-generation, off-the-shelf immunotherapy with strong therapeutic potential for TNBC, particularly in the context of metastasis, immune evasion, and treatment resistance.
Authors
- Ryan Hon
- Lili Yang (ORCID: https://orcid.org/0000-0001-6568-0404)
- Aiqi Zhao
- Catherine Zhang
- Y. Nathan
- Jie Huang (ORCID: https://orcid.org/0000-0003-3842-6181)
- Yan-Ruide Li (ORCID: https://orcid.org/0000-0002-9858-300X)
- Karine Sargsyan (ORCID: https://orcid.org/0000-0001-5853-4994)
- David Lin (ORCID: https://orcid.org/0000-0001-5695-9446)
- Yuan Yuan (ORCID: https://orcid.org/0009-0000-3599-471X)
- Zhe Li (ORCID: https://orcid.org/0000-0003-0493-8322)
- Xinyuan Shen
- Yanxin Tian
- Yichen Zhu (ORCID: https://orcid.org/0009-0008-9188-066X)
Institutions
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Parker Institute for Cancer Immunotherapy (US)
- Broad Center (US)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1186/s13045-025-01736-9
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 8.36